Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer

Blockade of CDK7 Reverses Endocrine Therapy Resistance in Breast Cancer

Cyclin-dependent kinase (CDK)-7 inhibitors are emerging as promising drugs for the treatment of different types of cancer that show chemotherapy resistance. Evaluation of the effects of CDK7 inhibitor, THZ1, alone and combined with tamoxifen is of paramount importance. Thus, in the current work, we...

Full description

Bibliographic Details
Main Authors: Yasmin M. Attia, Samia A. Shouman, Salama A. Salama, Cristina Ivan, Abdelrahman M. Elsayed, Paola Amero, Cristian Rodriguez-Aguayo, Gabriel Lopez-Berestein
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:International Journal of Molecular Sciences
Subjects:
breast cancer
estrogen receptor
resistance
tamoxifen
cyclin-dependent kinase 7
c-Myc
Online Access:https://www.mdpi.com/1422-0067/21/8/2974

Internet

https://www.mdpi.com/1422-0067/21/8/2974

Similar Items